Data Mining Differential Clinical Outcomes Associated with Drug Regimens Using Adverse Event Reporting Data

Overview

Journal Nat Biotechnol

Specialty Biotechnology

Date 2016 Jul 13

PMID 27404875

Citations 43

Authors

Mayur Sarangdhar

Scott Tabar

Charles Schmidt

Akash Kushwaha

Krish Shah

Jeanine E Dahlquist

Anil G Jegga

Bruce J Aronow

Affiliations

Soon will be listed here.

Citing Articles

Mining and analysis of dizziness adverse event signals in postoperative analgesia patients based on the FDA adverse event reporting system database.

Zhou F, He H, Zhang Z, Gao J Front Pharmacol. 2025; 16:1488469.

PMID: 40017599 PMC: 11865249. DOI: 10.3389/fphar.2025.1488469.

Investigating Sodium-Glucose Cotransporter 2 Inhibitors Versus Other Glucose-Lowering Drugs on Ventricular Arrhythmias or Sudden Cardiac Death Using the US FDA Adverse Event Reporting System.

Xu B, Zhang T, Kang B, Yang X, Li S, Chen J Cardiovasc Drugs Ther. 2024; .

PMID: 39630411 DOI: 10.1007/s10557-024-07653-2.

Tumor lysis syndrome signal with the combination of encorafenib and binimetinib for malignant melanoma: a pharmacovigilance study using data from the FAERS database.

Xia S, Xu J, Yan K, Noguchi Y, Sarangdhar M, Yan M Front Pharmacol. 2024; 15:1413154.

PMID: 39314755 PMC: 11417307. DOI: 10.3389/fphar.2024.1413154.

Sodium-glucose cotransporter 2 inhibitors and renal cancer in the US FDA adverse event reporting system.

Xu B, Zhou J Eur J Clin Pharmacol. 2024; 80(12):1959-1966.

PMID: 39285057 DOI: 10.1007/s00228-024-03759-6.

The involvement of the Stat1/Nrf2 pathway in exacerbating Crizotinib-induced liver injury: implications for ferroptosis.

Guo L, Ma J, Xiao M, Liu J, Hu Z, Xia S Cell Death Dis. 2024; 15(8):600.

PMID: 39160159 PMC: 11333746. DOI: 10.1038/s41419-024-06993-z.

References

Sakaeda T, Tamon A, Kadoyama K, Okuno Y . Data mining of the public version of the FDA Adverse Event Reporting System. Int J Med Sci. 2013; 10(7):796-803. PMC: 3689877. DOI: 10.7150/ijms.6048. View

Bohm R, Hocker J, Cascorbi I, Herdegen T . OpenVigil--free eyeballs on AERS pharmacovigilance data. Nat Biotechnol. 2012; 30(2):137-8. DOI: 10.1038/nbt.2113. View

Tatonetti N, Ye P, Daneshjou R, Altman R . Data-driven prediction of drug effects and interactions. Sci Transl Med. 2012; 4(125):125ra31. PMC: 3382018. DOI: 10.1126/scitranslmed.3003377. View

Tamura T, Sakaeda T, Kadoyama K, Okuno Y . Aspirin- and clopidogrel-associated bleeding complications: data mining of the public version of the FDA adverse event reporting system, AERS. Int J Med Sci. 2012; 9(6):441-6. PMC: 3410363. DOI: 10.7150/ijms.4549. View

Bennett C, Starko K, Thomsen H, Cowper S, Sartor O, Macdougall I . Linking drugs to obscure illnesses: lessons from pure red cell aplasia, nephrogenic systemic fibrosis, and Reye's syndrome. a report from the Southern Network on Adverse Reactions (SONAR). J Gen Intern Med. 2012; 27(12):1697-703. PMC: 3509314. DOI: 10.1007/s11606-012-2098-1. View

Bate A, Lindquist M, Edwards I, Olsson S, Orre R, Lansner A . A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol. 1998; 54(4):315-21. DOI: 10.1007/s002280050466. View

Grigoriev I, Zu Castell W, Tsvetkov P, Antonov A . AERS spider: an online interactive tool to mine statistical associations in Adverse Event Reporting System. Pharmacoepidemiol Drug Saf. 2014; 23(8):795-801. DOI: 10.1002/pds.3561. View

Butwicka A, Frisen L, Almqvist C, Zethelius B, Lichtenstein P . Risks of psychiatric disorders and suicide attempts in children and adolescents with type 1 diabetes: a population-based cohort study. Diabetes Care. 2015; 38(3):453-9. PMC: 4338504. DOI: 10.2337/dc14-0262. View

Hoffman K, Dimbil M, Erdman C, Tatonetti N, Overstreet B . The Weber effect and the United States Food and Drug Administration's Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010. Drug Saf. 2014; 37(4):283-94. PMC: 3975089. DOI: 10.1007/s40264-014-0150-2. View

10.

Qureshi Z, Seoane-Vazquez E, Rodriguez-Monguio R, Stevenson K, Szeinbach S . Market withdrawal of new molecular entities approved in the United States from 1980 to 2009. Pharmacoepidemiol Drug Saf. 2011; 20(7):772-7. DOI: 10.1002/pds.2155. View

11.

Harpaz R, DuMouchel W, LePendu P, Bauer-Mehren A, Ryan P, Shah N . Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system. Clin Pharmacol Ther. 2013; 93(6):539-46. PMC: 3857139. DOI: 10.1038/clpt.2013.24. View

12.

Noren G, Sundberg R, Bate A, Ralph Edwards I . A statistical methodology for drug-drug interaction surveillance. Stat Med. 2008; 27(16):3057-70. DOI: 10.1002/sim.3247. View

13.

Hoffman K, Demakas A, Dimbil M, Tatonetti N, Erdman C . Stimulated reporting: the impact of US food and drug administration-issued alerts on the adverse event reporting system (FAERS). Drug Saf. 2014; 37(11):971-80. PMC: 4206770. DOI: 10.1007/s40264-014-0225-0. View

14.

Zhao S, Nishimura T, Chen Y, Azeloglu E, Gottesman O, Giannarelli C . Systems pharmacology of adverse event mitigation by drug combinations. Sci Transl Med. 2013; 5(206):206ra140. PMC: 3963511. DOI: 10.1126/scitranslmed.3006548. View

15.

Moodley I . Review of the cardiovascular safety of COXIBs compared to NSAIDS. Cardiovasc J Afr. 2008; 19(2):102-7. PMC: 3975213. View

16.

OConnor N, Dargan P, Jones A . Hepatocellular damage from non-steroidal anti-inflammatory drugs. QJM. 2003; 96(11):787-91. DOI: 10.1093/qjmed/hcg138. View

17.

Cai M, Xu Q, Pan Y, Pan W, Ji N, Li Y . ADReCS: an ontology database for aiding standardization and hierarchical classification of adverse drug reaction terms. Nucleic Acids Res. 2014; 43(Database issue):D907-13. PMC: 4383906. DOI: 10.1093/nar/gku1066. View

18.

Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A . DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2010; 39(Database issue):D1035-41. PMC: 3013709. DOI: 10.1093/nar/gkq1126. View

19.

Sakaeda T, Kadoyama K, Minami K, Okuno Y . Commonality of drug-associated adverse events detected by 4 commonly used data mining algorithms. Int J Med Sci. 2014; 11(5):461-5. PMC: 3970098. DOI: 10.7150/ijms.7967. View

20.

Sarangdhar M, Kushwaha A, Dahlquist J, Jegga A, Aronow B . Using Systems Biology-based Analysis Approaches to Identify Mechanistically Significant Adverse Drug Reactions: Pulmonary Complications from Combined Use of Anti-TNFα Agents and Corticosteroids. AMIA Jt Summits Transl Sci Proc. 2013; 2013:151-5. PMC: 3814486. View